Operating CF
$5.01B
Capex
−$857.50M
Free Cash Flow
$4.16B
FCF Margin
+82.9%
Cash flow waterfall for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026
Free cash flow: $4.16B
Cash flow breakdown for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $5.01B | $5.01B |
| Capital Expenditure | −$857.50M | $4.16B |
| Free Cash Flow | $4.16B | $4.16B |
| Other Investing | −$848.00M | $3.31B |
| Share Buybacks | −$3.79B | −$485.30M |
| Dividends Paid | −$374.30M | −$859.60M |
| Other Financing & FX | $737.20M | −$122.40M |
| Net Cash Decrease | −$122.40M | −$122.40M |
- Operating Cash Flow$5.01B
- Capital Expenditure−$857.50M
- Free Cash Flow$4.16B
- Other Investing−$848.00M
- Share Buybacks−$3.79B
- Dividends Paid−$374.30M
- Other Financing & FX$737.20M
- Net Cash Decrease−$122.40M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement